Bluebird bio (BLUE) received an unsolicited, nonbinding buyout proposal from Ayrmid for
an upfront cash payment of $4.50 a share and a one-time contingent value right of $6.84 a share, payable on reaching a net sales milestone.
Bluebird had agreed to be acquired by funds managed by Carlyle (CG) and SK Capital Partners for $3 a share in cash and a one-time contingent value right of $6.84 a share payable upon achieving a net sales milestone.
Ayrmid didn't submit any proposal as part of the earlier review of alternatives, bluebird bio said Friday in a statement.
Bluebird bio said it "remains subject to the terms of the merger agreement" with Carlyle and SK Capital, and the board "has not changed its recommendation in support of the merger."
The board is reviewing the Ayrmid offer, which is "subject to certain conditions and further negotiations between the parties, including confirmatory diligence," blubird bio said.
The shares of bluebird bio jumped 9.1% in recent after-hours trading.
Price: 4.45, Change: +0.37, Percent Change: +9.07
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.